1. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial
- Author
-
Tomaniak, Mariusz, Chichareon, Ply, Onuma, Yoshinobu, Deliargyris, Efthymios N., Takahashi, Kuniaki, Kogame, Norihiro, Modolo, Rodrigo, Chang, Chun Ching, Rademaker-Havinga, Tessa, Storey, Robert F., Dangas, George D., Bhatt, Deepak L., Angiolillo, Dominick J., Hamm, Christian, Valgimigli, Marco, Windecker, Stephan, Steg, Philippe Gabriel, Vranckx, Pascal, Serruys, Patrick W., Bertrand, Olivier F., Plante, Sylvain, Van Geuns, Robert-Jan, Hofma, Sjoerd H., Royaards, Kees-Jan, Slagboom, Ton, Suryapranata, Harry, Umans, Victor A. W. M., Rensing, Benno, van der Harst, Pim, Magro, Michael, Barbato, Emanuel, Aminian, Adel, Benit, Edouard, Janssens, Luc, Vrolix, Mathias, Buysschaert, Ian, Carrie, Didier, Barraud, Pascal, Teiger, Emmanuel, Koning, Ren, Farzin, Beygui, Morelle, Jean-francois, Isaaz, Karl, Maillard, Luc, Abdellaoui, Mohamed, Brunel, Philippe, Angioi, Michael, Lantelme, Pierre, Sabate, Manel, Albarran Gonzalez-Trevilla, Agustin, Cardiology, Graduate School, ACS - Atherosclerosis & ischemic syndromes, ACS - Microcirculation, ACS - Heart failure & arrhythmias, and Cardiovascular Centre (CVC)
- Subjects
Male ,Ticagrelor ,Internationality ,Time Factors ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,Severity of Illness Index ,Tertiary Care Centers ,Coronary artery disease ,0302 clinical medicine ,Cause of Death ,030212 general & internal medicine ,610 Medicine & health ,Original Investigation ,Aspirin ,DUAL ANTIPLATELET THERAPY ,Continuity of Patient Care ,Clopidogrel ,Treatment Outcome ,CLOPIDOGREL ,Platelet aggregation inhibitor ,Drug Therapy, Combination ,Female ,Cardiology and Cardiovascular Medicine ,INTERVENTION ,medicine.drug ,Acute coronary syndrome ,medicine.medical_specialty ,Hemorrhage ,Risk Assessment ,Drug Administration Schedule ,03 medical and health sciences ,Percutaneous Coronary Intervention ,Internal medicine ,medicine ,Humans ,Acute Coronary Syndrome ,Dose-Response Relationship, Drug ,RECEPTOR ,business.industry ,Percutaneous coronary intervention ,IN-VITRO ,medicine.disease ,Survival Analysis ,PLATO ,Conventional PCI ,business ,Platelet Aggregation Inhibitors ,Follow-Up Studies - Abstract
Key PointsQuestionWhat are the benefits and risks of continuing aspirin in addition to P2Y12 receptor inhibition with ticagrelor among patients with acute coronary syndrome between 1 month and 12 months after percutaneous coronary intervention? FindingsIn this nonprespecified, post hoc analysis of the GLOBAL LEADERS randomized clinical trial, beyond 1 month after percutaneous coronary intervention in acute coronary syndrome, aspirin was associated with increased bleeding risk and appeared not to add to the benefit of ticagrelor on ischemic events. MeaningThe findings of this hypothesis-generating analysis pave the way for further trials evaluating aspirin-free antiplatelet strategies after percutaneous coronary intervention.ImportanceThe role of aspirin as part of antiplatelet regimens in acute coronary syndromes (ACS) needs to be clarified in the context of newer potent P2Y12 antagonists. ObjectiveTo evaluate the benefit and risks of aspirin in addition to ticagrelor among patients with ACS beyond 1 month after percutaneous coronary intervention (PCI). Design, Setting, and ParticipantsThis is a nonprespecified, post hoc analysis of GLOBAL LEADERS, a randomized, open-label superiority trial comparing 2 antiplatelet treatment strategies after PCI. The trial included 130 secondary/tertiary care hospitals in different countries, with 15991 unselected patients with stable coronary artery disease or ACS undergoing PCI. Patients had outpatient visits at 1, 3, 6, 12, 18, and 24 months after index procedure. InterventionsThe experimental group received aspirin plus ticagrelor for 1 month followed by 23-month ticagrelor monotherapy; the reference group received aspirin plus either clopidogrel (stable coronary artery disease) or ticagrelor (ACS) for 12 months, followed by 12-month aspirin monotherapy. In this analysis, we examined the clinical outcomes occurring between 31 days and 365 days after randomization, specifically in patients with ACS who, within this time frame, were assigned to receive either ticagrelor alone or ticagrelor and aspirin. Main Outcomes and MeasuresThe primary outcome was the composite of all-cause death or new Q-wave myocardial infarction. ResultsOf 15968 participants, there were 7487 patients with ACS enrolled; 3750 patients were assigned to the experimental group and 3737 patients to the reference group. Between 31 and 365 days after randomization, the primary outcome occurred in 55 patients (1.5%) in the experimental group and in 75 patients (2.0%) in the reference group (hazard ratio [HR], 0.73; 95% CI, 0.51-1.03; P=.07); investigator-reported Bleeding Academic Research Consortium-defined bleeding type 3 or 5 occurred in 28 patients (0.8%) in the experimental group and in 54 patients (1.5%) in the reference arm (HR, 0.52; 95% CI, 0.33-0.81; P=.004). Conclusions and RelevanceBetween 1 month and 12 months after PCI in ACS, aspirin was associated with increased bleeding risk and appeared not to add to the benefit of ticagrelor on ischemic events. These findings should be interpreted as exploratory and hypothesis generating; however, they pave the way for further trials evaluating aspirin-free antiplatelet strategies after PCI. Trial RegistrationClinicalTrials.gov identifier: NCT01813435.This secondary analysis of the GLOBAL LEADERS randomized clinical trial evaluates the benefit and risks of aspirin in addition to ticagrelor among patients with acute coronary syndrome beyond 1 month after percutaneous coronary intervention.
- Published
- 2019